FASLG and systemic lupus erythematosus: aPL mediated complement activation in the brain is also a potential source of nervous system toxicity and dysfunction.6 These antibodies were present in 61% of SLE patients and in about half of whom the presence of aPL was associated with clinical thrombotic complication.